PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Pyxis Oncology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.76+0.08 (+4.76%)

Close on Oct 19, 2026

Market cap: $112.63M
P/E (TTM): –
Dividend yield: –

Pyxis Oncology, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	15	19	9.66	179	275	8.08	–
Short-Term Investments	51	107	110	–	–	–	–
Cash & Short-Term Investments	67	127	119	179	275	8.08	–
Prepaid Expenses & Other	3.78	4.04	3.83	5.85	2.47	0.02	–
Other Current Assets	0.63	0.43	0.33	0.38	0.08	0.02	–
Total Current Assets	72	132	125	187	279	8.10	–
Property, Plant & Equipment	8.00	9.90	12	11	1.01	1.10	–
Gross Property, Plant & Equipment	15	15	15	13	2.12	1.57	–
Accumulated Depreciation	-7.01	-5.23	-3.60	-1.83	-1.12	-0.47	–
Operating Lease Right-of-Use Assets	11	12	13	14	0.23	0.84	–
Intangible Assets	0	2.60	24	–	–	–	–
Other Long-Term Assets	–	–	–	–	0.11	0.11	–
Total Assets	92	157	174	211	280	10	–
Accounts Payable	11	4.86	3.90	7.10	12	1.08	–
Accrued Expenses	8.55	11	13	25	6.59	2.00	–
Current Portion of Leases	1.69	1.45	1.23	–	0.17	0.62	–
Deferred Revenue (Current)	–	–	7.66	–	–	–	–
Total Current Liabilities	21	18	26	32	19	3.69	–
Long-Term Leases	17	19	20	19	–	0.17	–
Operating Lease Liabilities	19	20	21	19	0.17	0.78	–
Deferred Tax Liabilities	–	0	2.16	–	–	–	–
Total Liabilities	38	36	48	51	19	3.85	–
Common Stock	0.06	0.06	0.05	0.03	0.03	0.00	–
Additional Paid-In Capital	496	484	412	373	353	0.10	–
Retained Earnings	-443	-364	-286	-212	-92	-16	–
Comprehensive Income & Other	0.05	0.17	0.06	–	–	–	–
Shareholders' Equity	53	121	126	161	261	-16	-2.87
Total Equity	53	121	126	161	261	-16	-2.87
Total Liabilities & Equity	92	157	174	211	280	10	–
Shares Outstanding(shares)	63	60	45	35	32	1.29	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 82.8%
Operating margin: -664.6%
Net margin: -640.3%
Return on equity, FY2025: -91.4%

Financial strength

Current ratio: 1.34
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 68.6%

Valuation

P/E ratio: –
Price to sales: 8.13
Price to book: 9.84
Dividend yield: –